American Journal of Ophthalmology
Volume 136, Issue 1 , Pages 41-46 , July 2003

Plasma homocysteine is elevated in patients with exfoliation syndrome

This study was presented in part at the Annual Meeting of the American Academy of Ophthalmology, Orlando, Florida, October 2002.

  • Roberto M Vessani, MD

      Affiliations

    • Department of Ophthalmology, The New York Eye and Ear Infirmary, New York, New York (R.M.V., R.R., M.J.), USA
    • ,
  • Robert Ritch, MD

      Affiliations

    • Department of Ophthalmology, The New York Eye and Ear Infirmary, New York, New York (R.M.V., R.R., M.J.), USA
    • Department of Ophthalmology, The New York Medical College, Valhalla, New York (R.R.), USA
    • Corresponding Author InformationInquiries to Robert Ritch, MD, Glaucoma Service, Department of Ophthalmology, The New York Eye and Ear Infirmary, 310 East 14th St, New York, NY 10003, USA; fax: (212) 420-8743
    • ,
  • Jeffrey M Liebmann, MD

      Affiliations

    • Department of Ophthalmology, New York University School of Medicine and the Manhattan Eye, Ear and Throat Hospital, New York, New York (J.M.L.), USA
    • ,
  • Mark Jofe, MD

      Affiliations

    • Department of Ophthalmology, The New York Eye and Ear Infirmary, New York, New York (R.M.V., R.R., M.J.), USA

,Accepted 3 January 2003.

References 

  1. Ritch R, Schlötzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol. 2001;45:265–315
  2. Ritch R. Exfoliation syndrome (the most common identifiable cause of open-angle glaucoma). J Glaucoma. 1994;3:176–178
  3. Clarke R, Daily L, Robinson K, et al.  Hypermocysteinemia (an independent risk factor for vascular disease). N Engl J Med. 1991;324:1149–1155
  4. Stampfer MJ, Malinow MR, Willet WC, et al.  A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877–881
  5. Perry IJ, Refsum H, Morris RW, et al.  Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995;346:1395–1398
  6. Mitchell P, Wang JJ, Smith W. Association of pseudoexfoliation with increased vascular risk. Am J Ophthalmol. 1997;124:685–687
  7. Linnér E, Popovic V, Gottfries CG, et al.  The exfoliation syndrome in cognitive impairment of cerebrovascular or Alzheimer’s type. Acta Ophthalmol Scand. 2001;79:283–285
  8. Leblhuber F, Walli J, Artner-Dworzak E, et al.  Hyperhomocysteinemia in dementia. J Neural Transm. 2000;107:1469–1474
  9. Cursiefen C, Hündel A, Schonherr U, Naumann GOH. Pseudoexfoliation syndrome in patients with branch and central retinal vein thrombosis. Klin Monatsbl Augenheilkd. 1997;211:17–21
  10. Cursiefen C, Hammer T, Küchle M, et al.  Pseudoexfoliation syndrome in eyes with ischemic central retinal vein occlusion. A histopathologic and electron microscopic study. Acta Ophthalmol Scand. 2001;79:476–478
  11. Karjalainen K, Tarkkanen A, Merenmies L. Exfoliation syndrome in enucleated haemorrhagic and absolute glaucoma. Acta Ophthalmol. 1987;65:320–322
  12. Vine AK. Hyperhomocysteinemia (a risk factor for central retinal vein occlusion). Am J Ophthalmol. 2000;129:640–644
  13. Brown BA, Marx JL, Ward TP, et al.  Homocysteine (a risk factor for retinal venous occlusive disease). Ophthalmology. 2002;109:287–290
  14. Pianka P, Almog Y, Man O, et al.  Hyperhomocysteinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion. Ophthalmology. 2000;107:1588–1592
  15. Weger M, Stanger O, Deutschmann H, et al.  Hyperhomocyst(e)inaemia, but not MTHFR C677T mutation, as a risk factor for non-arteritic ischaemic optic neuropathy. Br J Ophthalmol. 2001;85:803–806
  16. Yildirir A, Aybar F, Tokgozoglu L, et al.  Effects of hormone replacement therapy on plasma homocysteine and C-reactive protein levels. Gynecol Obstet Invest. 2002;53:54–58
  17. Nygard O, Nordrehaug JE, Refsum H, et al.  Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230–236
  18. Nikfardjam M, Graf S, Hornykewycz S, et al.  Homocysteine plasma levels in young patients with coronary artery disease. Relation to history of acute myocardial infarction and anatomical extent of disease. Thromb Res. 2001;103(Suppl 1):S35–39
  19. Malinow MR, Nieto FJ, Szklo M, et al.  Carotid artery intimal medial wall thickening and plasmahomocysteine in assymptomatic adults (the Atherosclerosis Risk in Communities Study). Circulation. 1993;87:1107–1113
  20. den Heijer M, Koster T, Blom HJ, et al.  Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334:759–762
  21. Bostom AG, Shemin D, Lapane KL, et al.  Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis (a case-control study). Atherosclerosis. 1995;114:93–103
  22. Brunelli T, Prisco D, Fedi S, et al.  High prevalence of mild hyperhomocysteinemia in patients with abdominal aortic aneurysm. J Vasc Surg. 2000;32:531–536
  23. Schumacher S, Schlötzer-Schrehardt U, Martus P, et al.  Pseudoexfoliation syndrome and aneurysms of the abdominal aorta. Lancet. 2001;357:359–360
  24. Hietanen J, Soisalon-Soininen S, Kivelä T, Tarkkanen A. Evaluation of the clinical association between exfoliation syndrome and abdominal aortic aneurysm. Acta Ophthalmol Scand. 2002;80:617–619
  25. Repo LP, Suhonen MT, Teräsvirta ME, Koivisto JK. Color Doppler imaging of the ophthalmic artery blood flow spectra of patients who have had a transient ischemic attack. Correlations with generalized iris transluminance and pseudoexfoliation syndrome. Ophthalmology. 1995;102:1199–1205
  26. Holló G, Lakatos P, Farkas K. Cold pressor test and plasma endothelin-1 concentration in primary open-angle glaucoma and capsular glaucoma. J Glaucoma. 1998;7:105–110
  27. Janciauskiene S, Krakau T. Alzheimer’s peptide (a possible link between glaucoma, exfoliation syndrome, and Alzheimer’s disease). Acta Ophthalmol Scand. 2001;79:328–329
  28. Brooks AMV, Gillies WE. The development of microneovascular changes in the iris in pseudoexfoliation of the lens capsule. Ophthalmology. 1987;94:1090–1097
  29. Friedburg D, Bischof G. Fluorescein angiographic features of the pseudoexfoliation syndrome. Glaucoma. 1982;4:13–16
  30. Sibour G, Finazzo C, Boles Carenini A. Monolateral pseudoexfoliatio capsulae (a study of choroidal blood flow). Acta Ophthalmol Scand. 1997;75(Suppl 224):13–14
  31. Yuksel N, Karabas VL, Demirci A, et al.  Comparison of blood flow velocities of the extraocular vessels in patients with pseudoexfoliation or primary open-angle glaucoma. Ophthalmologica. 2001;215:424–429
  32. Stamler JS, Osborne JA, Jaraki O, et al.  Adverse vascular effects of homocystine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993;91:308–318
  33. Mujumdar VS, Aru GM, Tyagi SC. Induction of oxidative stress by homocyst(e)ine impairs endothelial function. J Cell Biochem. 2001;82:491–500
  34. Torres L, Garcia-Trevijano ER, Rodriguez JA, et al.  Induction of TIMP-1 expression in rat hepatic stellate cells and hepatocytes (a new role for homocysteine in liver fibrosis). Biochim Biophys Acta. 1999;1455:12–22
  35. Garcia-Tevijano ER, Berasain C, Rodriguez JA, et al.  Hyperhomocysteinemia in liver cirrhosis (mechanisms and role in vascular and hepatic fibrosis). Hypertension. 2001;38:1217–1221
  36. Konstas AG, Marshall GE, Lee WR. Immunogold localisation of laminin in normal and exfoliative iris. Br J Ophthalmol. 1990;74:450–457
  37. Marshall GE, Konstas AG, Lee WR. Immunogold fine structural localization of extracellular matrix components in aged human cornea. II. Collagen types V and VI. Graefes Arch Clin Exp Ophthalmol. 1991;229:164–171
  38. Frost P, Blom HJ, Milos R, et al.  A candidate genetic risk factor for vascular disease (a common mutation in methylenetetrahydrofolate reductase). Nat Genetics. 1995;10:111–113
  39. Andersson A, Brattstrom L, Israelsson B, et al.  Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invest. 1992;22:79–87
  40. Desouza C, Keeber M, McNamara DB, Fonseca V. Drugs affecting homocysteine metabolism (impact on cardiovascular risk). Drugs. 2002;62:605–616
  41. Bostom AG, Eaton CB, Yanek L, et al.  Elevations in total plasma homocysteine in premature coronary artery, cerebrovascular and peripheral vascular disease. Atherosclerosis. 1993;102:121–124
  42. Lobo A, Naso A, Arheart K, et al.  Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12. Am J Cardiol. 1999;83:821–825
  43. Bostom AG, Garber C. Endpoints for homocysteine-lowering trials. Lancet. 2000;355:511–512

☆ This study was supported in part by an unrestricted grant from Pharmacia Corporation and by the Joseph and Barbara Cohen Research Fund of the New York Glaucoma Research Institute, New York, New York, and by an unrestricted grant from the Eye Bank for Sight Restoration, New York, New York.

PII: S0002-9394(03)00077-1

doi: 10.1016/S0002-9394(03)00077-1

American Journal of Ophthalmology
Volume 136, Issue 1 , Pages 41-46 , July 2003

Article Tools

* Image Usage & Resolution